8-K ·Filed Apr 9, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
Monitor the upcoming conference call for more details on clinical trial timelines and the potential of VMS063. The slight delay in the DECLARATION study results to Q3 2026 should be factored into investment decisions.
Final — all horizons settled through T+60d ⚠ clustered
IVVD ▼ -53.15% at T+60d
NEUTRAL call ✗ call lost -53.15% · α vs SPY -63.93% · entry $1.78 → $0.8340
T+1d
-1.12%
call -1.12% · α -1.06%
$1.76
settled 6mo ago
T+5d
-3.93%
call -3.93% · α -7.12%
$1.71
settled 6mo ago
T+20d
-17.98%
call -17.98% · α -25.55%
$1.46
settled 5mo ago
T+60d
-53.15%
call -53.15% · α -63.93%
$0.8340
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Invivyd announced progress in its VYD2311 program for COVID-19 prevention and the discovery of a new measles monoclonal antibody candidate, VMS063. The company provided updates on clinical trial advancements and pipeline progress.
Key Facts
- Invivyd announced progress in its REVOLUTION program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention
- The DECLARATION Phase 3 study for VYD2311 has been upsized by approximately 500 additional subjects
- Top-line results for the DECLARATION study are now expected in Q3 2026, shifting from mid-year guidance
- The company has aligned with the FDA on an initial pediatric study plan for VYD2311
- Invivyd announced the discovery and advancement of VMS063, a novel measles monoclonal antibody candidate
- The company plans to host a conference call on April 9, 2026, at 8:30 AM ET
Financial Impact
No financial impact disclosed
Risk Factors
- Clinical trial delays could impact the timeline for regulatory submissions
- The measles antibody candidate VMS063 is still in early development stages
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-148865 |
| Document: d147019dex992.htm | 0001193125-26-148865 |
| Document: d147019d8k.htm | 0001193125-26-148865 |
| Document: 0001193125-26-148865-index-headers.html | 0001193125-26-148865 |
| Document: 0001193125-26-148865-index.html | 0001193125-26-148865 |
| Document: 0001193125-26-148865.txt | 0001193125-26-148865 |
15 reports for IVVD
75% Hit rate best @ T+20▲ +35.85%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.8800 $0.8441 | ▼ −4.08% | ▼ −5.26% | $0.8221 (−6.58%) |
Aug 17, 2026 6w ago | 144 | $0.8680 $0.8198 | ▼ −5.55% | ▼ −4.56% | $0.8221 (−5.29%) |
Jul 6, 2026 12w ago | 8-K | $0.8340 $0.5350 | ▲ +35.85% | ▲ +35.29% | $0.8221 (+1.43%) |
Jun 16, 2026 15w ago | Press Release | $0.8918 $0.8008 | ▼ −10.20% | ▼ −10.40% | $0.8221 (−7.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.8125 $0.8037 | ▼ −1.08% | ▼ −2.97% | $0.8221 (+1.18%) |
Jun 9, 2026 16w ago | Press Release | $0.9900 $0.9418 | ▼ −4.87% | ▼ −6.32% | $0.8221 (−16.96%) |
Jun 1, 2026 17w ago | Press Release | $1.22 $0.8724 | ▼ −28.49% | ▼ −27.19% | $0.8221 (−32.61%) |
May 14, 2026 20w ago | 8-K | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
May 14, 2026 20w ago | Press Release | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
Apr 9, 2026 25w ago | 8-K | $1.78 $1.46 | ▼ −17.98% | ▼ −25.55% | $0.8221 (−53.81%) |
Showing 10 of 15
US Market Status
Market Closed — Opens Mon (64h 35m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access